enVVeno Medical Corporation Warrants
NVNOW
NVNOW was delisted on the 26th of May, 2023.
1 hedge funds and large institutions have $24 invested in enVVeno Medical Corporation Warrants in 2023 Q1 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 0 reducing their positions, and 1 closing their positions.
50% less funds holding
Funds holding: 2 → 1 (-1)
79% less capital invested
Capital invested by funds: $114 → $24 (-$90)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$86 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NFSG
1
Newbridge Financial Services Group
Boca Raton,
Florida
| $24 | – | – | – |
|
|
2
UBS Group
Zurich,
Switzerland
| – | -$86 | -4,275 | Closed |
|
NVNOW Hedge Fund Activity: Q1 2023 in Review
1 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in enVVeno Medical Corporation Warrants (NVNOW) for Q1 2023, worth a combined $24 — down 79% from $114 a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of NVNOW and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was UBS Group, exiting entirely with an estimated $86 sold.
- 1 institutional investor held enVVeno Medical Corporation Warrants (NVNOW) as of Q1 2023, down from 2 in Q4 2022.
- Funds reported $24 of enVVeno Medical Corporation Warrants stock for Q1 2023, down 79% quarter-over-quarter.
- 0 funds opened new enVVeno Medical Corporation Warrants positions in Q1 2023 and 1 closed out, a net change of -1 holder.
- The largest enVVeno Medical Corporation Warrants seller in Q1 2023 was UBS Group, an estimated $86 sold.
Based on aggregated 13F filings for Q1 2023.